期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

NMDA受体拮抗剂与精神分裂症动物模型 被引量：2

Receptor Antagonist of NMDA and Animal Models of Schizophrenia
下载PDF
导出
摘要 精神分裂症是一类常见的精神疾病之一,由于其发病机制复杂,到目前为止病因尚未完全阐明,N-甲基-D-天门冬氨酸(N-methyl-D-aspartate,NMDA)受体拮抗剂能够较好地模拟精神分裂症的阳性症状、阴性症状以及认知功能障碍,近年来被广泛用以制作精神分裂症的动物模型。本文综述了苯环利定、地佐西平和氯胺酮这3种NMDA离子通道开放阻断剂与建立精神分裂症动物模型的关系。 Schizophrenia is one of the common mental diseases. Because the mechanism of the schizophrenia is significantly complicated,the cause is still unknown. N-methyl-D-aspartate receptor antagonist can simulate the positive and negative symptoms, as well as the cognitive disorder of schizophrenia. Thus it has been widely used to establish the animal models of schizophrenia. The relationship of the three blocking agents of ion channels （phencyclidine, MK-801, ketamine） and the establishment of schizophrenia animal models is reviewed in this article.
作者 卞士中 张健 刘伟丽 孙志红 顾振纶 蒋小岗
机构地区 苏州大学医学部法医学系 苏州中药研究所 苏州大学衰老与神经疾病实验室
出处 《法医学杂志》 CAS CSCD 2009年第6期443-446,共4页 Journal of Forensic Medicine
基金 香港保健协会资助项目(20060909-10HK)
关键词 司法精神病学 精神分裂症 综述[文献类型] 受体 N-甲基-D-天冬氨酸 forensic psychiatry schizophrenia review[publication type] receptors N-methyl-D-aspartate
分类号 R971 [医药卫生—药品] R749.3 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献26

  • 1Mouri A, Noda Y, Enomolo T, et al. Pheneyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment[J]. Neurochem Int,2007,51 (2-4):173- 184.
  • 2Shiigi Y, Casey DE. Behavioral effects of ketamine, an NMDA glutamatergie antagonist, in non-human primates[J]. Psychopharmaeology (Berl), 1999, 146 (1) : 67-72.
  • 3Paine TA, Carlezon WA. Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats[J]. Ne uropharmacology, 2009,56 (4) : 788-797.
  • 4Guo X, Hamilton PJ, Reish NJ, et al. Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia[J]. Neuropsychopharmacology, 2009,34(7) : 1659-1672.
  • 5Mohn AR, Gainetdinov RR, Caron MG, et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia[J]. Cell,1999,98(4): 427-436.
  • 6Northoff G, Richter A, Bermpohl F, et al. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI[J]. Schizophr Res,2005,72(2-3):235- 248,.
  • 7Javitt DC, Jayachandra M, Lindsley RW, et al. Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP) [J]. Clin Neurophysiol, 2000,111 (5) : 833-836.
  • 8Labrie V, Lipina T, Roder JC. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia[J]. Psychopharmacology(Berl), 2008,200(2) :217-230.
  • 9Wedzony K, Fijal K, Mackowiak M, et al. Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia[J]. Neuroscience,2008,153 (4) : 1370-1379.
  • 10Krystal JH, D'Souza DC, Mathalon D, et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development[J]. Psychopharmacology (Berl), 2003,169(3-4) :215-233.

二级参考文献9

  • 1[1]Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 1999, 20 : 201 ～ 225
  • 2[2]Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry, 2001, 158 :1367 ～ 1377
  • 3[3]Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate and GABA in schizophrenia: new evidence.Annu rev Pharmacol Toxicology, 2001,41 : 237 ～260
  • 4[4]Murray JB. Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J Psychology, 2002, 136 ( 3 ) : 319 ～ 327
  • 5[5]Farber NB, Newcomer JW, Olney JW. Glycine agonists: what can they teach us about schizophrenia? Arch Gen Psychiatry, 1999, 56:13 ～17
  • 6[6]Gao XM, Sakai K, Roberts RC, et al. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effect of schizophrenia. Am J Psychiatry,2000, 157: 1141 ～ 1149
  • 7[7]Smith RE, Haroutunian V, Davis KL, et al. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry, 2001, 158 : 1393 ～ 1399
  • 8[8]Sadikot AF, Burhan AM, Belanger MC, et al. NMDA receptor antagonists influence early development of GABA ergic interneurons in the mammalian striatum. Developmental Brain Reserarch, 1998, 105 :35 ～ 42
  • 9[9]Sobell JL, Mikesell MJ, McMurray CT. Genetic and etiopathophysiology of schizophrenia. Mayo Clin Proc, 2002, 77 : 1068 ～ 1082

同被引文献26

  • 1Weiser M, Davidson M, Noy S. Comments on risk for schizo- phrenia [J]. Schizophr Res, 2005, 79: 15-21.
  • 2Rung JP, Carlsson A, Ryd6n Markinhuhta K, et al. (+)-MK-801 induced social withdrawal in rats; a model for negative symp- toms of schizophrenia [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29(5): 827-832.
  • 3Zhang L, Shen C, Chu J, et al. Icariin decreases the expression of APP and BACE- 1 and reduces the 13- amyloid burden in an APP transgenic mouse model of Alzheimer's disease [J]. Int J Biol Sci, 2014, 10(2): 181-191.
  • 4梁家脉.淫羊藿善治以阴性症状为主的精神分裂症[J].中医杂志,2000,41(1):11-12.
  • 5Yoshimi N, Futamura T, Hashimoto K. Improvement of dizo- cilpine-induced social recognition deficits in mice by brexpip- razole, a novel serotonin-dopamine activity modulator [J]. Eur Neuropsychopharm, 2015, 25(3): 356-364.
  • 6Mutlu O, Ulak G, Celikyurt IK, et al. Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice [J]. Pharma- col Biochem Be, 2011, 98(3): 398-404.
  • 7Rog62 Z. Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object rec- ognition test in mice [J]. Pharmacol Rep, 2013, 65(5): 1401-1406.
  • 8Margherita B, Stefania B, Silvia F, et al. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for develop- ing effective antipsychotics: synthesis, biological characteriza- tion, and behavioral studies [J]. Med Chem, 2014, 57(22): 9578-9597.
  • 9Oh HK, Park S J, Bae SO, et al. Kami-ondam-tang, a tradition- al herbal prescription, attenuates the prepulse inhibition defi- cits and cognitive impairments induced by MK-801 in mice [J]. J Ethnopharmacol, 2013, 146(2): 600-607.
  • 10Irit GA, Moshe P, Igor T, et al. A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high effica- cy and good safety profile in mouse models of schizophre- nia [J]. Eur Neuro Psychopharm, 2014, 24(3): 425-436.

引证文献2

二级引证文献14

法医学杂志
2009年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部